Merck Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB ) said the Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. The study will be discontinued. "Although the results of this ACORN trial are disappointing, I would like to thank all of the patients, investigators, staff and our employees involved in conducting this trial," said Hamza Suria , AnaptysBio''s CEO. "We look forward to further advancement of imsidolimab for the treatment of GPP and hidradenitis suppurativa. AnaptysBio continues to utilize its strong cash position in a capital-efficient manner to advance three wholly-owned clinical-stage programs with $90 to $100 million anticipated net cash burn in 2022." The stock was declining 10.48% to $25.46 in premarket trading. Biogen, Eisai Amend Economic Agreement Related To Aduhelm Biogen, Inc. (NASDAQ: BIIB ) and Eisai Co.

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

NEW YORK , March 14, 2022 /PRNewswire/ -- Polaris Market Research recently published a research report on "Sleeping Aids Market Share, Size, Trends, Industry Analysis Report, By Product (Mattresses & Pillows, Sleep Laboratories, Medications, Sleep Apnea Devices); By Sleep Disorders; By Region; Segment Forecast, 2022 - 2030" in its research database. According to research report published by Polaris Market Research, the global Sleeping Aids Market size expected to reach to USD 118.31 Billion by 2030 from USD 64.08 Billion in 2021, at a compound annual growth rate (CAGR) of 7.1% during forecast period 2022 to 2030. Report Overview: Sleeping aids products are used in the form of medicines and medical devices to ensure proper monitoring, diagnosis, and treatment for sleep disturbances and disorders. Symptoms of sleep disorders include excessive daytime sleepiness, irregular breathing, or increased movement during sleep. Sleep disorders causes problems with the quality, timing, and amount of sleep, which result in irregular breathing and abnormal sleeping behaviors.

Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.

These companies are expected to produce rapid growth for sales and earnings, and have high dividend yields well-covered by cash flow.

The FDA has approved AstraZeneca Plc''s (NASDAQ: AZN ) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK ) to treat patients with early-stage breast cancer with certain mutations. The agency approved Lynparza (olaparib) for patients with a form of genetically mutated high-risk early-stage breast cancer called BRCA-mutated HER2-negative, who have already been treated with chemotherapy either before or after surgery. The approval was based on results from … Full story available on Benzinga.com

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) with the stream of -0.25% also noticed, India Merck & Co., Inc. (NYSE:MRK) encountered a rapid change of 0.48% in the last hour of Friday’s trading … The post Glowing Stock’s Review: CrowdStrike Holdings, Inc. (NASDAQ:CRWD), Merck & Co., Inc. (NYSE:MRK) appeared first on Stocks Equity .

VOO and other S&P 500 index funds report data that can lag for as much as two months behind. We compare metrics of VOO as of January 31, 2022 and those of SPY now to see how they differ.

Rising interest rates are a boon to blue chips like Manulife Financial. What are 3 reasons why MFC stock is one of the best high-yield blue chips? Find out.

The highest yielding stocks in any collection have become affectionately known as "dogs." Check out my list of 26 Dogcatcher Ideal Dogs for March.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced LYNPARZA® (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. The approval by the US Food and Drug Administration (FDA) was based on results from the OlympiA Phase III trial presented

The U.S. FDA has granted an additional indication for AstraZeneca (AZN) and Merck''s (MRK) Lynparza (olaparib) as an adjuvant treatment for a type of early-stage breast cancer.

Mirati's (MRTX) regulatory filing to the FDA for adagrasib in second-line NSCLC gets a longer-than-expected review period. MRTX is progressing well with the pipeline development for other candidates.